The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
-
Am J Geriatr Psychiatry · Mar 2002
Randomized Controlled Trial Clinical TrialOndansetron in the treatment of cognitive decline in Alzheimer dementia.
The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 microg/day and 100 microg/ day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.
-
Am J Geriatr Psychiatry · Jan 1997
Randomized Controlled Trial Comparative Study Clinical TrialA double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.
The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia. Twenty-eight elderly patients with dementia and agitated behaviors were randomly assigned to double-blind treatment with either trazodone (50-250 mg/day) or haloperidol (1-5 mg/day) for 9 weeks. ⋯ Improvement in individual areas suggested that repetitive, verbally aggressive, and oppositional behaviors responded preferentially to trazodone, whereas symptoms of excessive motor activity and unwarranted accusations responded preferentially to haloperidol. These results indicate that moderate doses of trazodone and haloperidol are equally effective for treatment of overall agitated behaviors in patients with dementia, but specific symptoms may respond preferentially to a particular agent.